16 completed, 3 terminated, 1 recruiting, 1 withdrawn. 17 Phase 2, 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 13, Terminated 3, Recruiting 1 |
| Phase 1 | 10 | Completed 6, Terminated 2, Recruiting 1, Withdrawn 1 |
Follow gossypol acetic acid: new trials by email Literature Review of gossypol acetic acid trials Research Report on gossypol acetic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma AT101(Anti-CD19 Chimeric Antigen Receptor T cell) - B-cell Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | AbClon | 82 | 2022-03-15 | 2022-05-26 |
| Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide - Recurrent Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 10 | 2016-04-14 | 2023-12-28 |
| Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia Lenalidomide, R-(-)-Gossypol Acetic Acid, Laboratory Biomarker Analysis - Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 5 | 2015-07-09 | 2020-06-16 |
| Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer AT-101, Docetaxel, Cisplatin - Laryngeal Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 55 | 2012-03-01 | 2023-07-20 |
| A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck AT-101, Docetaxel - Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 35 | 2010-06-01 | 2016-03-31 |
| Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer Tarceva plus AT-101 - Carcinoma, Non Small Cell Lung | Phase 1 | Withdrawn | University of Alabama at Birmingham | 2010-02-01 | 2015-05-08 | |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery R-(-)-gossypol acetic acid, paclitaxel, carboplatin - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2009-07-01 | 2013-01-10 |
| R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer AT-101, Bicalutamide, LHRH agent - Adenocarcinoma of the Prostate, Stage IV Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2014-12-18 |
| Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery R-(-)-gossypol acetic acid - Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2009-02-01 | 2014-05-07 |
| R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer R-(-)-gossypol acetic acid, pharmacological study, laboratory biomarker analysis - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2008-11-01 | 2014-05-12 |
| Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme R-(-)-gossypol acetic acid, laboratory biomarker analysis - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 56 | 2008-01-01 | 2017-08-11 |
| A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel - Hormone Refractory Prostate Cancer | Phase 2 | Completed | Ascenta Therapeutics | 220 | 2007-10-01 | 2010-11-09 |
| R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer R-(-)-gossypol acetic acid, cisplatin, etoposide - Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2007-09-01 | 2014-04-02 |
| A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer AT-101 and docetaxel, placebo and docetaxel - Non-small Cell Lung Cancer | Phase 2 | Completed | Ascenta Therapeutics | 106 | 2007-09-01 | 2010-08-27 |
| An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer AT-101 - Locally Advanced Esophageal or GE Junction Cancer | Phase 1 / Phase 2 | Terminated | Ascenta Therapeutics | 13 | 2007-08-01 | 2013-01-04 |
| Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer AT-101, topotecan - Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Ascenta Therapeutics | 36 | 2006-11-01 | 2010-08-24 |
| Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma AT-101, Rituximab - Follicular Lymphoma | Phase 2 | Completed | Ascenta Therapeutics | 23 | 2006-10-01 | 2010-08-27 |
| Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC AT-101 - Prostate Cancer | Phase 1 / Phase 2 | Completed | Ascenta Therapeutics | 76 | 2006-02-01 | 2011-06-29 |
| Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia AT-101 - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Ascenta Therapeutics | 19 | 2006-01-01 | 2010-08-13 |
| A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer AT-101 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | Ascenta Therapeutics | 27 | 2005-12-01 | 2010-08-24 |
Showing 20 of 21. Sign in to see all of them.
Neoplasms (6) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Follicular (3) · Prostatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Small Cell Lung Carcinoma (2) · Adrenocortical Carcinoma (1) · Brain Neoplasms (1) · Burkitt Lymphoma (1) · Disease (1) · Glioblastoma (1) · Gliosarcoma (1)
Ascenta Therapeutics (9) · National Cancer Institute (NCI) (6) · Mayo Clinic (2) · University of Michigan Rogel Cancer Center (2) · AbClon (1) · University of Alabama at Birmingham (1)
United States (19) · Russia (3) · Ukraine (2) · South Korea (1)
Lance Leopold, MD (8) · Anne Traynor (1) · Asher Chanan-Khan (1) · Deok-hyun Yoon (1) · Francis Worden, MD (1) · Francisco Robert, M.D. (1) · John Fiveash, MD (1) · Maria Baggstrom (1) · Mark Stein (1) · Michael Menefee (1) · Paul Swiecicki, MD (1) · Robert DiPaola (1) · Sikander Ailawadhi, M.D. (1) · Thomas Kipps, MD, PhD (1)
PMID 21982118, PMID 31388792, PMID 38066564
P30CA015083 (2), U01CA062491 (2), U01CA132194 (2), N01CM00038 (1), N01CM00070 (1), N01CM62201 (1), N01CM62205 (1), N01CM62209 (1), P30CA014520 (1), U01CA062475 (1)